Galectin-9 as a biomarker of disease severity.
Cell Immunol
; 361: 104287, 2021 03.
Article
in English
| MEDLINE | ID: covidwho-1092989
ABSTRACT
Galectin-9 (Gal-9) is a ß-galactoside binding lectin known for its immunomodulatory role in various microbial infections. Gal-9 is expressed in all organ systems and localized in the nucleus, cell surface, cytoplasm and the extracellular matrix. It mediates host-pathogen interactions and regulates cell signalling via binding to its receptors. Gal-9 is involved in many physiological functions such as cell growth, differentiation, adhesion, communication and death. However, recent studies have emphasized on the elevated levels of Gal-9 in autoimmune disorders, viral infections, parasitic invasion, cancer, acute liver failure, atopic dermatitis, chronic kidney disease, type-2 diabetes, coronary artery disease, atherosclerosis and benign infertility-related gynecological disorders. In this paper we have reviewed the potential of Gal-9 as a reliable, sensitive and non-invasive biomarker of disease severity. Tracking changes in Gal-9 levels and its implementation as a biomarker in clinical practice will be an important tool to monitor disease activity and facilitate personalized treatment decisions.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Galectins
/
Immunomodulation
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Cell Immunol
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS